Media stories about Biopharmx Corp (NASDAQ:BPMX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biopharmx Corp earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.6848965790893 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities research analysts have commented on the stock. Maxim Group restated a “buy” rating and issued a $1.50 price target (down from $3.00) on shares of Biopharmx Corp in a report on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Biopharmx Corp in a report on Tuesday, September 19th.
Biopharmx Corp (NASDAQ BPMX) traded up 0.9586% during midday trading on Friday, reaching $0.2949. 1,235,160 shares of the company’s stock were exchanged. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $0.90. The company’s market cap is $23.49 million. The firm has a 50-day moving average price of $0.30 and a 200 day moving average price of $0.46.
Biopharmx Corp (NASDAQ:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. On average, analysts expect that Biopharmx Corp will post ($0.24) EPS for the current fiscal year.
In related news, major shareholder Franklin Resources Inc acquired 250,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $0.34 per share, for a total transaction of $85,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
TRADEMARK VIOLATION WARNING: This story was published by BBNS and is owned by of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-biopharmx-corp-bpmx-share-price/1698924.html.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with our FREE daily email newsletter.